Compare Inovio Pharmaceuticals Inc (INO) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs McDonald's Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while McDonald's Corp trades at $235.7 (market cap $163.38B). The key difference: McDonald's Corp is far larger — about 1368.1× Inovio Pharmaceuticals Inc's market cap, and McDonald's Corp pays a 3.34% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and McDonald's Corp for 164 Days on average.
| INO | MCD | |
|---|---|---|
Market Cap | $119.42M | $163.38B |
Volume | 2,789,649 | 4,647,229 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $341.06 |
52-Week Low | $0.66 | $230.88 |
Typical Hold Time | 43 Days | 164 Days |
Enterprise Value | $90.75M | $217.15B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
McDonald's (MCD) trades at $236.9, up 1.91% for the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $26.89B and net income of $8.56B, supported by a 57.38% gross margin. Recent news highlights a new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $286.95 price target, but technical indicators and macroeconomic headwinds pose risks. Investment opportunity lies in McDonald's resilient franchise model and dividend yield, though inflation and execution of new initiatives are key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
